Skip to content

Application and effect analysis of erector spinae plane block for cardiac surgery

Application and effect analysis of erector spinae plane block for cardiac surgery

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100046786
Enrollment
Unknown
Registered
2021-05-28
Start date
2021-06-01
Completion date
Unknown
Last updated
2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients undergoing elective cardiac surgery

Interventions

Control group 1:Myofascial plane block, 0.9% sodium chloride, total volume 30ml
MFPB group 1:Myofascia plane block, 0.375% ropivacaine, 30ml
Control group 2:Myofascial plane block with 0.9% sodium chloride, 30ml. Regional block catheter was placed and pulse analgesic pump (0.9% sodium chloride, 8ml/h) was connected
MFPB goup 2:Myofascial plane block, 0.375% ropivacaine, 30ml.Regional block catheter was placed and pulse analgesic pump (0.2% ropivacaine, 8ml/h) was connected

Sponsors

Zhongshan Hospital, Fudan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.No gender limitation, aged 18 to 80 years; 2.ASA classification I-III; 3.Body mass index (BMI) 18-31; 4.NYHA classification I-III; 5.Elective heart surgery; 6.Voluntary participation and signing of informed consent.

Exclusion criteria

Exclusion criteria: 1.Participating in other clinical trials; 2.Surgery with deep hypothermia circulatory arrest surgery, re-surgery or emergency surgery; 3.Patients with preoperative liver or kidney dysfunction (ALT, AST, SCR or BUN increased to more than 1.5 times the normal value); 4.Patients with coronary heart disease, asthma, severe COPD, active infective endocarditis or pulmonary hypertension; 5.Preoperative chronic pain or long-term use of analgesics; 6.Known abuse of alcohol, drugs or narcotics; 7.People who are known to be allergic to research drugs; 8.Dementia or preoperative mental disorders, unable to do not cooperate or communicate; 9.Expected survival time less than 24 hours; 10.Women in pregnancy or lactation.

Design outcomes

Primary

MeasureTime frame
QoR-15 score;

Secondary

MeasureTime frame
QoR-15 score;Visual analogue scale;The first time patients controlled analgesia demand time;The number of compressions and invalid times for patients with intravenous analgesia;Total amount of sufentanil;Remedial analgesia rate;Exhaust time;Oxygenation index;Mechanical ventilation duration;Duration of intensive care unit stay;Time of thoracic canal removal;The hospitalization time;The comfort score was followed up to assess the occurrence of chronic pain;Routine blood;Blood glucose;

Countries

China

Contacts

Public ContactGuo Kefang

Zhongshan Hospital, Fudan University

guo.kefang@zs-hospital.sh.cn+86 13817706936

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026